🇺🇸 FDA

Intelligence · Clinical Pipeline

Phase II Pipeline Programs

Proof-of-concept and dose-finding clinical programs in Phase II development.

Programs
7,238

Quick answer

NovaPharmaNews tracks 7,238 phase ii pharmaceutical pipeline programs from ClinicalTrials.gov. Proof-of-concept and dose-finding clinical programs in Phase II development.

Top sponsors

Page 101 of 151

  1. Placebo

    IONIS PHARMACEUTICALS INC

    Hypertension

    phase 2 small molecule completed

    2 trials

  2. Placebo

    BRIGHT MINDS BIOSCIENCES INC.

    Addiction

    phase 2 small molecule completed

    1 trial

  3. Placebo

    Alnylam Netherlands B.V.

    Hypertension

    phase 2 small molecule completed

    1 trial

  4. Placebo

    Jazz Pharmaceuticals Ireland Limited

    Parkinson Disease

    phase 2 small molecule completed

    1 trial

  5. Placebo

    Jazz Pharmaceuticals Ireland Limited

    Viruria

    phase 2 small molecule completed

    1 trial

  6. Placebo

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid Use Disorder

    phase 2 small molecule active

    1 trial

  7. Placebo

    MapLight Therapeutics

    Schizophrenia

    phase 2 small molecule active

    1 trial

  8. Placebo

    Teva Pharma GmbH

    Primary Progressive Multiple Sclerosis

    phase 2 small molecule completed

    1 trial

  9. Placebo

    BRIGHT MINDS BIOSCIENCES INC.

    Bipolar Depression

    phase 2 small molecule terminated

    1 trial

  10. Placebo

    LEXICON PHARMACEUTICALS, INC.

    Postherpetic Neuralgia

    phase 2 small molecule completed

    1 trial

  11. Placebo

    PTC THERAPEUTICS, INC.

    Leigh Syndrome

    phase 2 small molecule completed

    1 trial

  12. Placebo

    PTC THERAPEUTICS, INC.

    Friedreich's Ataxia

    phase 2 small molecule completed

    1 trial

  13. Placebo

    Spero Therapeutics

    Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD)

    phase 2 small molecule completed

    1 trial

  14. Placebo (10 mM sodium acetate, 9.0% (w/v) sucrose, 0.02% (w/v) polysorbate 20, pH 5.2), EPINEPHRINE , Briquilimab

    Jasper Therapeutics

    Chronic Spontaneous Urticaria

    phase 2 small molecule active

    1 trial

  15. Placebo (blinded)

    LEXICON PHARMACEUTICALS, INC.

    Diabetic Peripheral Neuropathic Pain

    phase 2 small molecule completed

    1 trial

  16. Placebo (for dupilumab)

    Regeneron UK Limited

    Nasal Polyps

    phase 2 small molecule completed

    1 trial

  17. Placebo (matched to VX-121 suspension)

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 2 small molecule completed

    1 trial

  18. Placebo + Inactive Marijuana (0% THC)

    BRIGHT MINDS BIOSCIENCES INC.

    Marijuana Use

    phase 2 small molecule completed

    1 trial

  19. Placebo + Placebo, cagrilintide semaglutide, cagrilintide semaglutide, cagrilintide semaglutide, cagrilintide semaglutide, cagrilintide semaglutide

    NovoThirteen

    Type 2 diabetes and painful diabetic peripheral neuropathy

    phase 2 small molecule active

    1 trial

  20. Placebo - Sodium Chloride 9 mg/ml (0.9%) - Solution for injection, ARO-DM1

    Sarepta Therapeutics

    Type 1 Myotonic Dystrophy

    phase 2 small molecule active

    1 trial

  21. Placebo 100 mg tablet, NMD670, Placebo 300 mg tablet, NMD670

    Lacuna Pharma Pty Ltd

    Type 3 spinal muscular atrophy

    phase 2 small molecule active

    1 trial

  22. Placebo A, NNC0487-0111, NNC0487-0111, NNC0487-0111, Placebo C tablets, NNC0487-0111, METFORMIN , NNC0487-0111, NNC0487-0111, NNC0487-0111, DAPAGLIFLOZIN , NNC0487-0111

    NovoThirteen

    Type 2 Diabetes

    phase 2 small molecule active

    1 trial

  23. Placebo A, NNC0519-0130, Ozempic 0.5 mg solution for injection in pre-filled pen

    NovoThirteen

    Chronic Kidney Disease, with or without Type 2 diabetes, Obesity

    phase 2 small molecule active

    1 trial

  24. Placebo A, Semaglutide B Placebo, Ozempic 0.5 mg solution for injection in pre-filled pen

    NovoThirteen

    type 2 diabetes

    phase 2 small molecule active

    1 trial

  25. Placebo C, Semaglutide B 3.0 mg/ml PDS290, Semaglutide B placebo PDS290 pen-injector, Cagrilintide A 10 mg/mL cartridge, NNC0174-0833 A Placebo

    NovoThirteen

    Non-alcoholic steatohepatitis (NASH)

    phase 2 small molecule active

    1 trial

  26. Placebo Infusion

    United Therapeutics Europe Ltd

    Brain Injuries, Traumatic

    phase 2 mab active

    1 trial

  27. Placebo Oral Tablet

    Mereo BioPharma Group plc

    Alpha 1-Antitrypsin Deficiency

    phase 2 small molecule completed

    1 trial

  28. Placebo PH20 SC – prefilled syringe (placebo to Efgartigimod PH20 SC – prefilled syringe), Efgartigimod

    argenx

    Antibody-Mediated Rejection

    phase 2 small molecule active

    1 trial

  29. Placebo RO7269162, RO7269162, RO7269162, RO7269162, FLORBETABEN (18F), FLUTEMETAMOL (18F)

    Hoffmann-La Roche

    Alzheimer’s Disease

    phase 2 small molecule active

    1 trial

  30. Placebo capsule

    Ipsen

    Fibrodysplasia Ossificans Progressiva

    phase 2 small molecule active

    1 trial

  31. Placebo capsules

    BRIGHT MINDS BIOSCIENCES INC.

    Pain Threshold

    phase 2 small molecule completed

    1 trial

  32. Placebo comparator, intramuscular injection, TRI-001

    Ferring Pharmaceuticals

    Patients with Chronic Limb Threatening Ischemia (CLTI) due to Peripheral Arterial Disease (PAD)

    phase 2 small molecule active

    1 trial

  33. Placebo d'amiloride, AMILORIDE, AMILORIDE

    Pari Pharma GmbH

    Patients treated with lithium carbonate for a bipolar disorder treated for at least 5 years and with a urine concentration defect.

    phase 2 small molecule active

    1 trial

  34. Placebo de macitentan 10 mg, MACITENTAN

    Pari Pharma GmbH

    Inoperable Chronic thromboembolic pulmonary hyperTension, Pneumology

    phase 2 small molecule active

    1 trial

  35. Placebo for ABBV-142

    AbbVie Deutschland GmbH & Co. KG

    Idiopathic Pulmonary Fibrosis

    phase 2 small molecule active

    1 trial

  36. Placebo for ACP-204 capsules

    Lacuna Pharma Pty Ltd

    Lewy Body Dementia Psychosis (LBDP)

    phase 2 small molecule active

    1 trial

  37. Placebo for AG-946 oral tablet., AG-946, AG-946

    Lacuna Pharma Pty Ltd

    Sickle Cell Disease

    phase 2 small molecule active

    1 trial

  38. Placebo for AMG 133, AMG 133

    Amgen

    Type 2 Diabetes Mellitus

    phase 2 small molecule active

    1 trial

  39. Placebo for AMG 451, Rocatinlimab

    Amgen

    Moderate-to-severe Asthma

    phase 2 small molecule active

    1 trial

  40. Placebo for AMG 732 will consist of site-sourced normal saline in sterile single-use vials or ampoules, AMG 732

    Amgen

    Thyroid Eye Disease

    phase 2 small molecule active

    1 trial

  41. Placebo for AZD2693 Solution for Injection, Placebo for AZD2693 Solution for Injection

    AstraZeneca AB

    Non-cirrhotic non-alcoholic steatohepatitis with fibrosis

    phase 2 small molecule active

    1 trial

  42. Placebo for AZD4144, AZD4144

    AstraZeneca AB

    Sepsis-associated acute kidney injury (AKI)

    phase 2 small molecule active

    1 trial

  43. Placebo for AZD5148, AZD5148

    AstraZeneca AB

    Recurrence of Clostridioides difficile Infection

    phase 2 small molecule active

    1 trial

  44. Placebo for Bepirovirsen Solution for Injection, 150 mg/mL SSD

    GlaxoSmithKline

    Hepatitis B

    phase 2 small molecule active

    1 trial

  45. Placebo for GSK3739937 Tablets are tablets for oral administration and visually match the active GSK3739937 Tablets with the omission of the active ingredient. Placebo for GSK3739937 Tablets are white, round, film coated tablets containing no markings.

    ViiV Healthcare Pty Ltd

    HIV Infections

    phase 2 small molecule active

    1 trial

  46. Placebo for GSK5784283.

    GlaxoSmithKline

    Asthma

    phase 2 small molecule active

    1 trial

  47. Placebo for JNJ-95597528, JNJ-95597528

    Janssen-Cilag International N.V.

    Moderate to Severe Atopic Dermatitis

    phase 2 small molecule active

    1 trial

  48. Placebo for KER-012, cibotercept

    Keros Therapeutics

    Pulmonary Arterial Hypertension

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many Phase II pipeline programs are in the directory?

7,238 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.